What is the translation of " FUNCTION ABNORMALITIES " in Slovenian?

• motnje delovanja
• nenormalnosti delovanja
• nenormalno delovanje

Examples of using Function abnormalities in English and their translations into Slovenian

Liver function abnormalities have been associated with PAH.
Nenormalnosti jetrne funkcije so povezane s PAH.

Hepato-biliary disorders: liver function abnormalities.
Bolezni jeter, žolčnika in žolčevodov: nenormalnosti jetrne funkcije.

Evere liver function abnormalities(determined by laboratory tests).
Hude nenormalnosti v delovanju jeter(ugotavljajo se z laboratorijskim testiranjem).

Hepatobiliary disorders: rare: hepatitis not known: liver function abnormalities.
Žolčnika in žolčevodov redke: hepatitis pogostnost ni znana: nenormalno delovanje jeter.

Any patient developing significant liver function abnormalities during treatment must be monitored closely.
Vsakega bolnika, pri katerem se med zdravljenjem pojavijo pomembne motnje delovanja jeter, morate skrbno nadzorovati.

The Sitaxentan population also included patients(N= 53) who had discontinued another endothelin receptor antagonist due to liver function abnormalities.
Populacija, ki je dobivala sitaksentan, je vključevala tudi bolnike(n= 53), ki so zaradi nepravilnosti jetrnega delovanja nehali uporabljati kakšen drug antagonist endotelinskih receptorjev.

Any patient developing significant liver function abnormalities during treatment must be monitored closely.
Vsakega bolnika, pri katerem se med zdravljenjem pojavijo pomembne motnje delovanja jeter, je treba skrbno spremljati.

Toremifene treatment has been associated with changes in liver enzyme levels(increases of transaminases) and in very rare occasions with more severe liver function abnormalities(jaundice).
Zdravljenje s toremifenom je bilo povezano s spremembami vrednosti jetrnih encimov(povečanje vrednosti transaminaz) in v zelo redkih primerih s hudimi motnjami delovanja jeter(zlatenica).

Hepatic enzymes and function abnormalities, cholestasis and jaundice, hepatocellular damage and hepatitis, cholangitis.
Nenormalnosti jetrnih encimov in delovanja jeter, holestaza in zlatenica, okvara jetrnih celic in hepatitis, holangitis.

The most commonly reported treatment-related events(investigator assessment) are: liver function abnormalities, diarrhoea, headache, rash, hypertension.
Najpogosteje so poročali(po oceni raziskovalca) o naslednjih z zdravilom povezanih neželenih učinkih: nenormalnosti delovanja jeter, driska, glavobol, izpuščaj, hipertenzija.

Frequency of liver function abnormalities during combination antiretrovir l ther py(CART) and should be monitored according to standard practice.
Kombinirane protiretrovirusne terapije(combination antiretroviral ther py, CART)zaveč anomalij jetrne funkcije in jih je treba nadzirati v skladu s standardno prakso.

The most commonly reported ADRs(investigator assessment) are liver function abnormalities(3.5%), diarrhoea(2.7%), headache(1.8%), nausea(1.7%), rash(1.5%).
Z zdravljenjem povezani neželeni učinki(po oceni raziskovalca), o katerih so najpogosteje poročali, so nenormalnosti delovanja jeter(3, 5%), driska(2, 7%), glavobol(1, 8%), navzea(1, 7%) in izpuščaj(1, 5%).

Endocrine system Thyroid function abnormalities or worsening of pre-existing thyroid disorders have been reported with the use of alpha interferons, including Pegasys.
Endokrini sistem Pri jemanju interferonov alfa, vključno z zdravilom Pegasys, so opazili nepravilno delovanje ščitnice ali poslabšanje predhodno obstoječih motenj delovanja ščitnice.

Patients with pre-existing liver dysfunction including chronic active hepatitis have an increased frequency of liver function abnormalities during combination antiretroviral therapy and should be.
Bolniki s predhodno jetrno disfunkcijo, vključno s kroničnim aktivnim hepatitisom, imajo pri kombiniranem protiretrovirusnem zdravljenju povečano pogostnost nepravilnosti jetrne funkcije.

Any patient developing liver function abnormalities during treatment with IntronA must be monitored closely and treatment discontinued if signs and symptoms progress.
Vse bolnike, pri katerih se med zdravljenjem z zdravilom IntronA pojavijo motnje delovanja jeter, morate natančno spremljati in zdravljenje prekiniti, če se znaki in simptomi slabšajo.

Patients with pre-existing liver dysfunction, including chronic active hepatitis B or C, have an increased risk for liver function abnormalities including severe and potentially fatal hepatic adverse reactions.
Pri bolnikih z boleznimi jeter, vključno z aktivnim kroničnim hepatitisom B ali C, je tveganje za motnje delovanja jeter, vključno z resnimi in potencialno smrtnimi jetrnimi neželenimi učinki zvečano.

Not known:• reduced number of red blood cells(anaemia),• reduced number of thrombocytes,• migraine,• cough,• liver function abnormalities,• muscle and joint pain,• changes in kidney function(may be reversible upon discontinuation of treatment) including kidney failure,• flu-like symptoms,• increase in blood urea,• serum creatinine and serum potassium in patients with heart failure,• back pain and urinary track infection.
Pogostnost ni znana:• zmanjšano število rdečih krvnih celic(anemija)• zmanjšano število trombociov• migrena• kašelj• nenormalno delovanje jeter• bolečine v mišicah in sklepih• spremenjeno delovanje ledvic(ki se po prekinitvi zdravljenja lahko popravi), vključno z ledvično odpovedjo• gripi podobni simptomi• povečana količina sečnine v krvi• povečana količina kreatinina in kalija v serumu pri bolnikih s srčnim popuščanjem• bolečine v hrbtu in okužba urinarnega trakta.

Readministration to patients who previously had ASAT or ALATgt; 5 ULN during nevirapine therapy and had recurrence of liver function abnormalities upon readministration of nevirapine(see section 4.4).
Ponovno dajanje bolnikom, ki so imeli raven AST ali ALT med prejšnjim zdravljenjem z nevirapinomgt; 5-krat večjo od zgornje meje normalne laboratorijske vrednosti in pri katerih so se motnje jetrne funkcije ob ponovnem dajanju nevirapina ponovile(glejte poglavje 4.4).

Patients with pre-existing liver dysfunction including chronic hepatitis have an increased frequency of liver function abnormalities during combination antiretroviral therapy and should be monitored according to standard practice.
Pri bolnikih z obstoječimi motnjami delovanja jeter, vključno s kroničnim hepatitisom so, med kombinirano protiretrovirusno terapijo, motnje delovanja jeter lahko pogostejše in jih je treba spremljati v skladu s standardno prakso.

The most commonly reported adverse reactions in clinical trials(4,072 subjects treated at least with a dose from 10 mg to 300 mg) and post-marketing experience are gout flares, liver function abnormalities, diarrhoea, nausea, headache, rash and oedema.
Neželeni učinki, o katerih so najpogosteje poročali v kliničnem preskušanju(4.072 bolnikov, zdravljenih z odmerkom zdravila od 10 mg do 300 mg) in v obdobju trženja so zagoni putike, nenormalnosti delovanja jeter, driska, navzea, glavobol, izpuščaj in edem.

Patients with pre-existing liver dysfunction including chronic active hepatitis have an increased frequency of liver function abnormalities during combination therapy and should be monitored according to standard practice.
Pri bolnikih z obstoječo jetrno disfunkcijo, tudi kroničnim aktivnim hepatitisom, se med kombiniranim zdravljenjem poveča pogostnost motenj jetrnega delovanja, zato jih moramo spremljati v skladu s standardno prakso.

Summary of the safety profile The most commonly reported adverse reactions in clinical trials(4,072 subjects treated at least with a dose from 10 mg to 300 mg) and post-marketing experience are gout flares, liver function abnormalities, diarrhoea, nausea, headache, rash and oedema.
Povzetek varnostnega profila Neželeni učinki, o katerih so najpogosteje poročali v kliničnem preskušanju(4.072 bolnikov, zdravljenih z odmerkom zdravila od 10 mg do 300 mg) in v obdobju trženja so zagoni putike, nenormalnosti delovanja jeter, driska, navzea, glavobol, izpuščaj in edem.

Patients with pre-existing liver dysfunction including chronic hepatitis have an increased frequency of liver function abnormalities during CART and should be monitored according to standard practice.
Pri bolnikih z obstoječo okvaro jeter, vključno s kroničnim hepatitisom, so nepravilnosti delovanja jeter med kombiniranim protiretrovirusnim zdravljenjem pogostejše; takšne bolnike je treba spremljati v skladu z običajno prakso.

Patients with pre-existing liver dysfunction including chronic active hepatitis have an increased frequency of liver function abnormalities during combination antiretroviral therapy and should be monitored according to standard practice.
Bolniki z obstoječo motnjo jetrne funkcije, tudi kroničnim aktivnim hepatitisom, imajo med kombiniranim protivirusnim zdravljenjem pogosteje moteno jetrno delovanje, zato jih je potrebno spremljati v skladu s standardno prakso.

Patients with pre-existing liver dysfunction including chronic active hepatitis have an increased frequency of liver function abnormalities during combination antiretroviral therapy and should be monitored according to standard practice.
Pri bolnikih s predhodnimi motnjami delovanja jeter, vključno s kroničnim aktivnim hepatitisom, je pogostnost funkcijskih nepravilnosti jeter med kombiniranim protiretrovirusnim zdravljenjem večja in jih je treba spremljati skladno z ustaljeno prakso.

Patients with pre-existing liver dysfunction including chronic active hepatitis have an increased frequency of liver function abnormalities during combination antiretroviral therapy and should be monitored according to standard practice.
Bolniki s predhodnimi obolenji jeter, vključno s kroničnim aktivnim hepatitisom, imajo med kombiniranim protiretrovirusnim zdravljenjem povečano pogostnost nepravilnosti delovanja jeter in jih je zato treba spremljati v skladu s standardnimi postopki.

Patients with pre-existing liver dysfunction, including chronic active hepatitis, have an increased frequency of liver function abnormalities during combination antiretroviral therapy and should be monitored according to standard practice.
Bolniki z že obstoječo jetrno disfunkcijo, vključno s kroničnim aktivnim hepatitisom, imajo v času kombinirane protiretrovirusne terapije(CART-combination antiretroviral therapy) več anomalij jetrne funkcije in jih je treba nadzirati v skladu s standardno prakso.